Abstract
What is already known on this topic?The global burden of chronic obstructive pulmonary disease (COPD) is serious. Pneumococcal infection is associated with acute exacerbations of COPD (AECOPD). The 23-valent pneumococcal polysaccharide vaccine (PPSV23) is recommended for COPD patients to decrease AECOPD due to pneumococcus, but evidence on the immunogenicity of PPSV23 in COPD patients is limited.What is added by this report?This study showed good immunogenicity of one dose of PPSV23 in COPD patients. Antibody levels against all 23 vaccine serotypes were assessed before and four weeks after vaccination of COPD patients with one dose of PPSV23. The percent of COPD patients who had two-fold increases in pneumococcal antibody levels following vaccination ranged from 65.2% (serotype 3) to 94.4% (serotype 2). There were statistically significant differences in immunogenicity by serotype.What are the implications for public health practice?This study supports current recommendations for PPSV23 vaccination of COPD patients in China to provide protection from pneumococcal diseases.
Highlights
23-valent pneumococcal polysaccharide vaccine (PPSV23) is recommended for patients with chronic obstructive pulmonary disease (COPD) to prevent acute exacerbations (AECOPD) from pneumococcal diseases [1,2], the immunogenicity of PPSV23 in COPD patients is not known for all 23 vaccine serotypes
We found that PPSV23 provided good immunogenicity, with 2-fold increases in antibody levels ranging from 65.2% to 94.4%, and significant increases in geometric mean concentrations (GMCs), but with little difference by age, presence of comorbidities, and COPD severity for most serotypes
This study found that immunogenicity provided by 1 dose of PPSV23 in COPD patients was good
Summary
Yan Li1; Ying Ma2; Zhijie An1; Chenyan Yue; Yamin Wang; Liye Wang; Yunqiu Liu; Xiaodong Yuan; Shuping Zhang; Qiang Ye3; Hong Li3; Keli Li1; Zundong Yin; Huaqing Wang1,#. Antibody levels against all 23 vaccine serotypes were assessed before and four weeks after vaccination of COPD patients with one dose of PPSV23. This study supports current recommendations for PPSV23 vaccination of COPD patients in China to provide protection from pneumococcal diseases. 23-valent pneumococcal polysaccharide vaccine (PPSV23) is recommended for patients with chronic obstructive pulmonary disease (COPD) to prevent acute exacerbations (AECOPD) from pneumococcal diseases [1,2], the immunogenicity of PPSV23 in COPD patients is not known for all 23 vaccine serotypes. We found that PPSV23 provided good immunogenicity, with 2-fold increases in antibody levels ranging from 65.2% to 94.4%, and significant increases in GMCs, but with little difference by age, presence of comorbidities, and COPD severity for most serotypes.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
